National Vital Statistics System

Outlook on the Opioids Global Market to 2027 - High Incidence of Chronic Pain in Adults and Demand for Strong Agonists are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Health, Pharmaceutical, Time, CAGR, Palliative care, Cough, Public health, Infection, COVID-19, United States drug overdose death rates and totals over time, Fentanyl, Safety, Death, Hydrocodone, Pethidine, Codeine, Morphine, Drug, Knowledge, Efficiency, National Vital Statistics System, OMT, Research, Pain, Hospital, Methadone, National, Chronic pain, Analgesic, Diarrhea, Oxycodone, Oxymorphone, Drug overdose, Incidence, Patient, Application, Awareness, CDC, Prevalence, Pain Clinic, Cereal, Poultry, Pharmaceutical industry

The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.

Key Points: 
  • The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.
  • Opioids essentially serve as pain relievers since they are composed of substances that relax muscles and alleviate pain and stress.
  • Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain.
  • Individuals diagnosed with terminal illnesses suffering from severe and chronic physical pain are the main recipient of these analgesics.

The Lancet: Disparities in life expectancy persist among racial and ethnic groups across the US

Retrieved on: 
Friday, June 17, 2022
American Indians, Article, Time, National Center for Health Statistics, Population, NVSS, Centers for Disease Control and Prevention timeline, Mortality, Smoking, COVID-19, Obesity, Alaska Natives, Academy of Medical Sciences (United Kingdom), 2009 Davis Cup, National Institute on Minority Health and Health Disparities, Map, Death, Institute for Health Metrics and Evaluation, Feedback, Institute, Life expectancy, University Place, Washington, Data visualization, Research, NCHS, API, Manuscript, National Vital Statistics System, Hypertension, University, Policy, Health, Sex, IHME, Medical statistics, Communication, Academy, Medicine, Multimedia, American, Diabetes, Use-centered design, Risk, Tutoring, Road, Pharmaceutical industry, Medical device, Oil, Lancet, Evaluation, AIAN, Black, White

New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.

Key Points: 
  • New study offers the first comprehensive, county-level life expectancy estimates in the US and highlights important differences among racial and ethnic groups.
  • The analysis reveals that despite overall life expectancy gains of 2.3 years (from 76.8 years in 2000 to 79.1 years in 2019) during the 20-year study period (20002019), disparities among racial and ethnic groups remain, with Black populations still experiencing shorter life expectancy than White populations.
  • "Gains in life expectancy are noteworthy but stop short of suggesting we're closing the gap that persists among different racial and ethnic groups.
  • The study's results highlight considerable variation in life expectancy among racial and ethnic groups, locations, and over time, exposing both positive and negative trends.

Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment

Retrieved on: 
Tuesday, November 16, 2021
Quality of life, Lofexidine, Betty Ford Center, Hazelden Betty Ford Foundation, OUD, National Institute on Drug Abuse, Clinical trial, Leadership, Methadone, Substance-related disorder, National Vital Statistics System, National, Controlled Substances Act, Pharmacotherapy, CDC, Lists of diseases, Naltrexone, Opioid, Man, Woman, Foundation, Twitter, United States drug overdose death rates and totals over time, Research, LinkedIn, Hope, Speech disorder, Tan, Physician, Buprenorphine, Patient, Medicine, Pharmaceutical industry

However, treatment efficacy and patient retention have been limited meaning significantly fewer patients are using or seeking these non-opioid treatment options.

Key Points: 
  • However, treatment efficacy and patient retention have been limited meaning significantly fewer patients are using or seeking these non-opioid treatment options.
  • Through its upcoming clinical trial, Spark Biomedical ultimately seeks to broaden the footprint of readily available, effective treatment for acute withdrawal and long-term recovery support.
  • Research will be supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number 1R44DA053876-01.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.